OncoMatch/Clinical Trials/NCT05723107
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Is NCT05723107 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Chemotherapy and Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) for pancreatic cancer.
Treatment: Chemotherapy · Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) — This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — first line
who have not responded or progressed on first line chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tisch Hospital · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05723107 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages